Window Trial of Fluorescently Labeled Nivolumab-IRDye800 (Nivo800) in High Grade Glioma (HGG)

NCT07210632 · clinicaltrials.gov ↗

EARLY_PHASE1

Phase

RECRUITING

Status

38

Enrollment

OTHER

Sponsor class

Conditions

Brain Cancer
HGG
Glioma
High Grade Glioma
High Grade Gliomas
High Grade Glioma (III or IV)
High Grade Glioma (HGG) of the Brain With BRAF Aberration

Interventions

DRUG: Nivolumab
DRUG: Nivolumab-IRDye800

Sponsor

Eben Rosenthal

Collaborators

[object Object]